Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.
Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.
Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.
BioRestorative Therapies (BRTX) announced a 1-for-4,000 reverse stock split to facilitate its planned listing on The Nasdaq Capital Market. The split is effective from October 27, 2021, with the temporary ticker symbol BRTXD. Following the split, outstanding shares will decrease from approximately 3.49 billion to 872,211. The company believes this action meets Nasdaq's initial listing requirements, enhancing its appeal to institutional investors and access to capital.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the nomination of Patrick F. Williams and David Rosa to its Board of Directors. This strategic move reflects the company's aim to enhance leadership with experienced professionals in the medical device industry. Williams, CFO at STAAR Surgical, and Rosa, CEO of NeuroOne, will bring valuable expertise to support BioRestorative's focus on cell therapies and overall growth. Their election is contingent upon the effectiveness of the company’s pending registration statement.
BioRestorative Therapies (OTC: BRTX) announced a significant milestone on September 23, 2021, as the Israeli Patent Office granted a Notice of Allowance for its ThermoStem program patent application. This patent will safeguard the use of implantable scaffolds that incorporate human brown adipose tissue stem cells, potentially treating various degenerative and metabolic disorders. CEO Lance Alstodt expressed satisfaction with the broader protection provided by this allowance compared to existing US patents, highlighting the technology's therapeutic relevance.
BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Australian Patent Office for its ThermoStem® Program. The patent covers an implantable scaffold using brown adipose-derived stem cells and methods of use to treat metabolic disorders. Initial preclinical research suggests that increased levels of brown fat can enhance caloric burning and reduce glucose and lipid levels, potentially lowering obesity and diabetes risks. The CEO emphasized the patent's importance for delivery methods in ongoing program development.
BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Japanese Patent Office for its ThermoStem® Program, which focuses on methodologies for deriving brown adipocytes from human brown adipose-derived stem cells. The patent underscores the potential of brown fat in improving metabolic processes, including calorie burning and glucose regulation. CEO Lance Alstodt highlighted the growing value of their intellectual property. The company is utilizing stem cell protocols for various therapies, including treatments for disc/spine diseases and obesity.
BioRestorative Therapies (OTC: BRTX) announces its annual stockholders meeting on August 17, 2021, at 10 a.m. EDT. Key proposals for vote include the reincorporation from Delaware to Nevada and a reverse stock split. Majority approval is required for these changes. Stockholders of record as of June 24, 2021, are encouraged to vote online or attend in person. The company focuses on developing stem cell-based therapies, with lead product BRTX-100 targeting chronic lower back pain.
BioRestorative Therapies (OTC: BRTX) announced the filing of a registration statement on Form S-1 with the SEC for a proposed underwritten public offering of its securities. The offering's completion depends on the registration's effectiveness and market conditions. If successful, the net proceeds will fund clinical trials for BRTX-100, research and development for the metabolic ThermoStem Program, and general corporate expenses.
BioRestorative Therapies invites investors to attend its presentation at the Emerging Growth Conference on June 9, 2021, at 10:45 AM Eastern Time. The event allows interaction with CEO Lance Alstodt and VP of R&D Francisco Silva. Attendees can ask questions, and a recording will be available post-event. BioRestorative focuses on stem cell therapies, with its leading product BRTX-100 targeting chronic lower back pain. The conference serves as a platform for public companies to present innovative solutions to investors.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the expansion of its Melville, NY research labs for clinical production of cell therapies.
The new cGMP facility will support the Phase 2 clinical trial for BRTX-100 and the ThermoStem® program, enhancing internal manufacturing capabilities.
As part of this initiative, the company plans to hire more employees, aligning operations with FDA and EMA regulations for clinical-grade cell production.
FAQ
What is the current stock price of Biorestorative Therapies (BRTX)?
What is the market cap of Biorestorative Therapies (BRTX)?
